Both parties have signed an agreement worth 518.62 billion Korean won (approximately 2.56 billion Chinese yuan), under which Samsung E&A will undertake the main construction project of Sartorius' bioprocessing facility located in Songdo, South Korea.

The factory is a production and research facility for biopharmaceutical raw materials, producing sterile bags, membrane filters, and cell culture media, and providing non-clinical CRO services.

Specifically, Samsung E&A will conduct the preliminary design for the factory and will be fully responsible for equipment procurement and construction, with the goal of completing the project by 2027.

Sartorius, founded in 1870, is a leading partner in life science research and the biopharmaceutical industry, providing products, equipment, and technical services to enterprises and various research institutions. The company has 13,500 employees worldwide, and for the fiscal year 2024, the group sales revenue is approximately €3.4 billion (about 26.6 billion yuan).

Previously, Sartorius announced the establishment of its Asian center in South Korea, initially declaring an investment of $100 million. The budget has since increased, and the company stated that it will invest heavily in South Korea to expand its business scale.

As an engineering project company under Samsung, Samsung E&A has a history of half a century and has successfully completed over 1,000 projects worldwide.

In recent years, the biopharmaceutical sector has become a key focus for Samsung E&A, and the collaboration with Sartorius is seen as an important step in expanding its global biopharmaceutical business.

In December of last year, Samsung E&A announced that it had secured a biofuel refinery construction project in Malaysia, with a contract value of up to $955 million (approximately 6.93 billion RMB).